Debug Stats | ### Total Build Time: 76 ms 40.085 KB CONCEPT_NAME gt=11 ms Completed: 11 ms rowSize= 368 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 586 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=1 ms Completed: 1 ms rowSize= 187 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=10 ms Completed: 10 ms rowSize= 557 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 4.072 KBCONCEPT_RELATIONSHIPS gt=26 ms Completed: 26 ms rowSize= 16.242 KBCONCEPT_GENES gt=21 ms Completed: 21 ms rowSize= 16.908 KBCONCEPT_XREFS gt=6 ms Completed: 6 ms rowSize= 1.169 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Relationships (49)
Relation Types: diso_to_anat : 24 diso_to_diso : 24 diso_to_phen : 1
Relationships: none : 8 associated_with : 1 is_abnormal_cell_of_disease : 7 is_associated_anatomic_site_of : 1 is_finding_of_disease : 1 is_normal_cell_origin_of_disease : 4 is_normal_tissue_origin_of_disease : 2 is_not_abnormal_cell_of_disease : 3 is_not_finding_of_disease : 1 is_not_molecular_abnormality_of_disease : 1 is_not_normal_cell_origin_of_disease : 4 is_primary_anatomic_site_of_disease : 1 isa : 5 may_be_abnormal_cell_of_disease : 1 may_be_cytogenetic_abnormality_of_disease : 2 may_be_finding_of_disease : 2 may_be_molecular_abnormality_of_disease : 4 permuted_term_of : 1 | |
DISO_to_DISO | 11 | |
AIDS ASSOC LYMPHOMA C0085090 | DISO_to_DISO | 10 | |
Complication Aspects C1171258 | DISO_to_PHEN | 10 | |
genetic aspects C0017399 | DISO_to_ANAT | 7 | |
Plasma Cells C0032112 | DISO_to_DISO | 7 | |
Diffuse Large B-Cell Lymphoma C0079744 | DISO_to_DISO | 6 | |
Mouth Neoplasms C0026640 | DISO_to_DISO | 5 | |
HIV Infections C0019693 | DISO_to_DISO | 5 | |
Lymphoma, B-Cell C0079731 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Atypical lymphocyte C0221277 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
B lymphoblast C1516097 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
B-Lymphocytes C0004561 | DISO_to_ANAT | | is_not_abnormal_cell_of_disease |
Cells, Reed-Sternberg C0085133 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
HEMOLYMPHORETICULAR TISSUE C1512398 | DISO_to_ANAT | | is_associated_anatomic_site_of |
Hematopoietic and Lymphatic System C1512394 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Hematopoietic and Lymphoid Cell C1512385 | DISO_to_ANAT | | is_primary_anatomic_site_of_disease |
Lymphatic System C0024235 | DISO_to_ANAT | | is_normal_tissue_origin_of_disease |
Lymphatic Tissue C0024296 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Lymphocyte C0024264 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Mature B-Cell C1513019 | DISO_to_ANAT | | is_not_normal_cell_origin_of_disease |
Myeloid Cells C0887899 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic B-Immunoblast C1513927 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic B-Lymphocyte C1513929 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Cell C0597032 | DISO_to_ANAT | | may_be_abnormal_cell_of_disease |
Neoplastic Centroblast C1514006 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Neoplastic Hematopoietic and Lymphoid Cell C1513983 |
|
Genes (10)
Species: human : 9 mouse : 1 | |
Mouse | LYN | 4067 | v-yes-1 Yamaguchi sarcoma viral related oncogene homolog | Previously, we reported that the K1 protein induced plasmablastic lymphomas in K1 transgenic mice, and that these lymphomas showed enhanced Lyn kinase activity. | Human | TIMP1 | 7076 | TIMP metallopeptidase inhibitor 1 | Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Further studies are presented on eighteen cases of high grade, large cell immunoblastic lymphoma in which expression at the RNA level of TIMP-1 and the metalloproteinase, 92 kDa gelatinase, were analyzed. | Human | TFRC | 7037 | transferrin receptor (p90, CD71) | However, transferrin receptor expression by certain histologic subtypes of lymphoma did not correlate with their morphologic grade: low-grade follicular lymphomas expressed the T9 antigen more frequently than diffuse low-grade lymphomas; diffuse small cleaved cell lymphomas were stained by OKT9 less often than other histologic subtypes of intermediate-grade lymphomas; and diffuse immunoblastic lymphomas expressed transferrin receptors less often than the other high-grade histologic subtypes of non-Hodgkins lymphoma. In attempting to identify antigens that are differentially expressed on tumor cells following transformation from follicular small cleaved cell lymphoma (FSC) to immunoblastic lymphoma (IL), we identified a unique epitope of the transferrin receptor (TfR). | Human | SPN | 6693 | sialophorin | The large cell immunoblastic lymphoma was of T-cell lineage, positive for the CD45RB, CD3, CD45RO, and CD43 antigens, and negative for the CD20 and CDw75 antigens. | Human | SDC1 | 6382 | syndecan 1 | All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. | Human | PAX5 | 5079 | paired box 5 | PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. | Human | KIT | 3815 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | CD117 expression can be detected sporadically in DLBCL (diffuse large B-cell lymphoma) of follicle center-cell origin and a subset of plasmablastic lymphomas | Human | IL9 | 3578 | interleukin 9 | However, it appears that IL-6 and/or IL-9 may play a prominent role in the tumor cell proliferation of Hodgkin;s disease (HD), anaplastic large-cell lymphoma, or immunoblastic lymphoma. | Human | CD22 | 933 | CD22 molecule | With the exception of some lymphoblastic lymphomas, high-grade B-cell lymphomas normally expressed the pan B-cell antigens CD19 and CD22 but only immunoblastic lymphomas consistently expressed the pan B marker CD20. | Human | MS4A1 | 931 | membrane-spanning 4-domains, subfamily A, member 1 | A skin biopsy led to the diagnosis of plasmablastic lymphoma in view of the presence of a dense nodular infiltrate invading the dermis and subcutaneous fat composed of large cells that expressed neither the leucocyte common antigen nor the B- and T-cell antigens CD20 and CD3, but which showed a strong immunostaining with plasma cell marker VS38c. With the exception of some lymphoblastic lymphomas, high-grade B-cell lymphomas normally expressed the pan B-cell antigens CD19 and CD22 but only immunoblastic lymphomas consistently expressed the pan B marker CD20. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. Histologic examination of lesional tissue revealed a lymphoid tumor with a high proliferation rate containing lymphoplasmacytoid cells that were reactive to the plasma cell marker VS38c but not to CD20 or CD79a; these are features of the recently reported non-Hodgkin;s lymphoma termed plasmablastic lymphoma. The large cell immunoblastic lymphoma was of T-cell lineage, positive for the CD45RB, CD3, CD45RO, and CD43 antigens, and negative for the CD20 and CDw75 antigens. |
|